Search
The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is a multifactorial Bayesian adaptive platform trial that aims to improve the way that S. aureus bloodstream infection, a globally common and severe infectious disease, is treated. In a world first, the SNAP trial will simultaneously investigate the effects of multiple intervention modalities within multiple groups of participants with different forms of S. aureus bloodstream infection.
Streptococcus pyogenes (also known as group A Streptococcus , Strep A) is an obligate human pathogen with significant global morbidity and mortality. Transmission is believed to occur primarily between individuals via respiratory droplets, but knowledge about other potential sources of transmission via aerosols or the environment is limited. Such knowledge is required to design optimal interventions to control transmission, particularly in endemic settings.
Five The Kids Research Institute Australia researchers working across diverse and highly impactful areas of child health research have been named as finalists for the 2023 Premier’s Science Awards.
Immediate plating of impetigo swabs is the gold standard for bacterial recovery but is rarely feasible in remote regions.
Asha Dylan Janessa Tim Bowen Barth Pickering Barnett BA MBBS DCH FRACP PhD GAICD FAHMS OAM B.Tech, MPH, PhD BSc PhD PhD Head, Healthy Skin and ARF
Asha John Jonathan Marianne Bowen Jacky Carapetis AM Mullane BA MBBS DCH FRACP PhD GAICD FAHMS OAM AM MBBS FRACP FAFPHM PhD FAHMS BSc (OT) Head,
Asha John Jonathan Marianne Bowen Jacky Carapetis AM Mullane BA MBBS DCH FRACP PhD GAICD FAHMS OAM AM MBBS FRACP FAFPHM PhD FAHMS BSc (OT) Head,
Skin disease has several serious complications including heart and kidney disease.
The Skin Health Situational Analysis was conducted in 2017 with and for stakeholders in the Kimberley region as a precursor to the SToP Trial to highlight all that was already known prior to commencement in 2018. It was completed to be a resource for communities in the Kimberley who would like to de
There are an estimated 5000 episodes per year of bloodstream infections due to Staphylococcus aureus (golden staph) in Australia and an associated mortality of 20%. Despite this, there is little clinical trials evidence to guide best management.